AI Article Synopsis

  • A boy with mosaic Down Syndrome and spinal muscular atrophy faced delayed diagnosis due to overlapping symptoms, complicating his motor development.
  • Born at 37 weeks with a normal Apgar score and without significant family history, he was diagnosed with an unbalanced male karyotype at 3 weeks old.
  • The final diagnosis of both conditions came at 27 months, after noticing muscle strength decline and other neurological issues during evaluations.

Article Abstract

A boy is presented in whom Down Syndrome mosaicism and spinal muscular atrophy by overlapping clinical symptoms delayed the diagnosis and caused complicated motor development. The boy from the first pregnancy was delivered vaginally, week 37, Apgar 10, birth weight 3,650 g. The mother, aged 30, had no family history of Down Syndrome or neuromuscular diseases. Primary diagnosis at the age of 3 weeks: unbalanced male karyotype -mos 47, XY+21 [22]/46, XY. At 20 months, the parents observed the disappearance of the high kneeling function and asked for a neurologist's consultation. The neurological examination showed symmetrically reduced muscle tone and symmetrically weakened knee and ankle tendon reflexes. The physiotherapeutic assessment revealed a symmetrical weakening of muscle strength and hand tremor (features characteristic of patients with spinal muscular atrophy). The final diagnosis, set at the age of 27 months, was thus the mosaic form of Down Syndrome and spinal muscular atrophy type 2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621056PMC
http://dx.doi.org/10.3389/fgene.2024.1483903DOI Listing

Publication Analysis

Top Keywords

spinal muscular
16
muscular atrophy
16
motor development
8
mosaic form
8
form syndrome
8
syndrome spinal
8
atrophy type
8
case report
4
report atypical
4
atypical motor
4

Similar Publications

Background: With the approval of disease-modifying treatments for 5q-spinal muscular atrophy (SMA), there is an increasing need for biomarkers for disease course and therapeutic response monitoring. Radially sampled Averaged Magnetization Inversion Recovery Acquisitions (rAMIRA) MR-imaging enables spinal cord (SC) gray matter (GM) delineation and quantification in vivo. This study aims to assess SC GM atrophy in patients with 5q-SMA and its associations with clinical disability.

View Article and Find Full Text PDF

Spinal cord injury (SCI) causes severe motor and sensory deficits, and there are currently no approved treatments for recovery. Nearly 70% of patients with SCI experience pathological muscle cocontraction and spasticity, accompanied by clinical signs such as patellar hyperreflexia and ankle clonus. The integration of epidural electrical stimulation (EES) of the spinal cord with rehabilitation has substantial potential to improve recovery of motor functions; however, abnormal muscle cocontraction and spasticity may limit the benefit of these interventions and hinder the effectiveness of EES in promoting functional movements.

View Article and Find Full Text PDF

Purpose: the purpose of this study was to evaluate the safety and usability of the ATLAS 2030 in children with Cerebral Palsy (CP) and Spinal Muscular Atrophy (SMA).

Materials And Methods: the sample consisted of six children, three with CP and three with SMA, who received eight sessions of robot-assisted gait therapy. Safety was measured by the presence of adverse events.

View Article and Find Full Text PDF

UBA1 is an E1 ubiquitin-activating enzyme that initiates the ubiquitylation of target proteins and is thus a key component of the ubiquitin signaling pathway. Three disorders are associated with pathogenic variants of the UBA1 gene: vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome, lung cancer in never smokers (LCINS), and X-linked spinal muscular atrophy (XL-SMA, SMAX2). We here report a case of infantile respiratory distress syndrome followed by continuing neuromuscular symptoms.

View Article and Find Full Text PDF

Background: The evidence on the link between cardiometabolic diseases (CMDs) and motor neuron diseases (MNDs) remains inconsistent. We aimed to determine whether there is an association of CMDs, namely, any cardiovascular disease, cardiac arrhythmia, heart failure, thromboembolic disease, hypertension, cerebrovascular disease, ischemic heart disease, diabetes mellitus type 2, and hypercholesterolemia with the risk and progression of MNDs.

Methods: We included 1463 MND patients (amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive spinal muscular atrophy (PSMA), and unspecified MND) diagnosed from January 1, 2015, to July 1, 2023, in Sweden according to the Swedish Motor Neuron Disease Quality Registry (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!